Welcome, Guest. Please login or register.
October 22, 2017, 10:41:12 PM

Login with username, password and session length

  • Total Members: 31678
  • Latest: 2247cg
  • Total Posts: 721091
  • Total Topics: 58495
  • Online Today: 387
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Pa-457  (Read 1586 times)

0 Members and 1 Guest are viewing this topic.

Offline john

  • Member
  • Posts: 21
« on: August 28, 2006, 03:13:52 PM »
Just Curious, I have been reading all the new conference information and I cant seem to find any news on pa 457. Anyone have any info on this?
Jon be good

Offline Eldon

  • Member
  • Posts: 2,664
Re: Pa-457
« Reply #1 on: August 28, 2006, 06:31:42 PM »
Hello John, it is Eldon. I was doing a little research today and I found out about some information on PA-457.

The Company's lead compound, bevirimat (PA-457), is the first in the new class of HIV drugs called Maturation Inhibitors that specifically block a late step in processing of the HIV Gag protein. Following bevirimat treatment, virus particles released from HIV-infected cells are non-infectious and virus replication is terminated. This antiviral target is unique to Panacos and the Company is building a strong intellectual property position around its ground-breaking discovery.

For more information you can go to: http://www.panacos.com/product_2.htm.

This should be of good help for you.

Have the BEST Day.

Offline J.R.E.

  • Member
  • Posts: 7,539
  • Joined Dec-2003 Living positive, since 1985.
Re: Pa-457
« Reply #2 on: August 29, 2006, 07:48:27 PM »
Hello John,

Heres a link in addition to the link that Eldon gave you. I believe the information is about the same ;


Story below ;

Drug 'blocks the spread of HIV' 
The drug interferes with a process which helps HIV infect new cells
Scientists are developing a new way of tackling HIV, using a drug which blocks the assembly of the virus.
US researchers, working with Panacos Pharmaceuticals which makes the drug, found it was effective in a small-scale human trial, New Scientist reports.

PA-457 will now be given in combination with other HIV drugs to people whose existing treatment is failing.

Experts said there was a lot of interest in PA-457, but warned it would not be available for some years.

 There is a lot of interest in this product

Keith Alcorn, National Aids Manual (NAM)

The demand for new forms of medication is great.

About 80% of people being treated for HIV show resistance to one or more of their drugs, a spokesman for Panacos said.

There are several existing ways of tackling HIV.

Many medications work by blocking reverse transcriptase, an enzyme which enables HIV to replicate within a cell.

Others disable protease, which helps to assemble the virus into particles to infect other cells.

"Shield 'disabled"

PA- 457, a derivative of betulinic acid, is a cheap by-product of the paper industry and one of a new class of drugs called maturation inhibitors.

It works by interfering with the production of the capsid protein, a conical "shield" which protects the genetic material of HIV inside it.

The research, also published in the Journal of Virology, showed PA-457 binds to the protein at a key stage of its development, meaning it forms instead into a "leaky sphere" which leaves the genetic material exposed.

Without its protective cone, HIV is defective and unable to infect other human cells.

Previous lab work on human cells infected with HIV by the University of Oklahoma and Panacos researchers has shown that PA-457 is effective on strains of the virus which are resistant to other anti-HIV drugs.

The small human trial of the drug last year reported that, given on its own, it rapidly clears most HIV from the blood.

New class

Further research, due to begin this month, will test how PA-457 works in combination with other drugs. Combination treatments are most effective because of the high levels of drug resistance seen in HIV treatment.

Forty-eight patients whose current treatment regimes are failing will either be given PA-457 or a dummy version along with their existing medication.

Even if results are positive, much larger studies will be needed to test the drug's effectiveness on more people and to see what combination of treatments works best.

It will be at least 2009 before the drug is on the market, the researchers warn.

HIV researcher Charles Boucher, of the University Hospital at Utrecht in the Netherlands, said: "It's a truly novel new class of drugs, and I really support their development.

"If [PA-457] turns out to be non-toxic, easy to use and not to select for resistance, it will find good use."

Keith Alcorn, senior editor at National Aids Manual (NAM), said: "This is a new class of drugs, and there is a lot of interest in this product.

"It stops the virus by interfering in one of the final stages in its assembly and stops it from 'budding out' from the wall of a cell."

He said much more research would be needed to show how safe and effective the drug was.

Current Meds ; Viramune, Epzicom, 20mg of Atorvastatin, 25 mg of Hydrochlorothiazide.
Amlodipine Besolate 5mg-- Updated 9/24/2017

Diagnosed positive in 1985,.. In October of 2003, My t-cell count was 16, Viral load was over 500,000, Percentage at that time was 5%. I started on  HAART on October 24th, 2003.

 As of 9/18/2017,  Viral load remains <40
CD 4 @358 /  CD4 % @ 13

 65 years young.


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.